Brand Name

Zemdri

Generic Name
Plazomicin
View Brand Information
FDA approval date: June 29, 2018
Form: Injection

What is Zemdri (Plazomicin)?

ZEMDRI is an aminoglycoside antibacterial indicated for the treatment of patients 18 years of age or older with Complicated Urinary Tract Infections including Pyelonephritis.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Plazomicin susceptibility profile in carbapenem-resistant Enterobacterales (CRE): a laboratory-based cross-sectional study from a tertiary care hospital in North India.
Plazomicin susceptibility profile in carbapenem-resistant Enterobacterales (CRE): a laboratory-based cross-sectional study from a tertiary care hospital in North India.
Journal: Indian journal of medical microbiology
Published: March 12, 2026
In vitro activity of ceftazidime-avibactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, cefiderocol, and plazomicin against non-fermenting Gram-negative isolates obtained from Bulgarian inpatients.
In vitro activity of ceftazidime-avibactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, cefiderocol, and plazomicin against non-fermenting Gram-negative isolates obtained from Bulgarian inpatients.
Journal: Acta microbiologica et immunologica Hungarica
Published: March 10, 2026
Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing Klebsiella pneumoniae.
Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing Klebsiella pneumoniae.
Journal: Antimicrobial agents and chemotherapy
Published: February 04, 2026
View All Latest Advances